Prasurel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prasurel

Quick Facts

Property Description
Active ingredient Prasugrel
Form Film-coated tablet
Pharmacological class P2Y12 Platelet Inhibitor (Antiplatelet Agent)
Origin Synthetic thienopyridine derivative
Classification Prodrug

What Type of Medicine is Prasurel and What is its Purpose?

Prasurel is a prescription-only medicine that contains the active substance Prasugrel, classified as an antiplatelet agent. This medication falls into the broad category often referred to as a blood thinner, and its sole purpose is its antithrombotic action, meaning it helps inhibit the body's tendency to form pathological blood clots, thereby promoting clear blood flow in the circulatory system.

Prasugrel is a synthetic prodrug belonging to the thienopyridine derivative class. The term prodrug signifies that the substance ingested is chemically inactive and relies on rapid metabolic conversion in the liver into its active chemical form to function effectively. The medication is typically used in clinical scenarios where consistent, strong platelet inhibition is required.

The Composition and Mechanism of Action

Prasurel is a single-ingredient product supplied as a film-coated tablet designed for oral administration. The active ingredient, Prasugrel, functions as a potent and consistent P2Y12 Platelet Inhibitor. Its key feature is that the active metabolite binds irreversibly to the P2Y12 receptor on the platelet surface. This permanent blockade ensures a sustained reduction in the platelet’s ability to aggregate for its entire lifespan, which is a key differentiating factor among antiplatelet therapies. This mechanism ensures that components in the blood responsible for initiating clots do not inappropriately stick together.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Prasurel?

Possible Side Effects and Safety Information

The safety profile of Prasurel (Prasugrel) is structured around the inherent risk associated with its potent antiplatelet action, as documented in official regulatory labeling. The primary safety characteristic is an increased potential for haemorrhage (bleeding) events, which is classified as a very common adverse reaction.

Adverse reactions are formally grouped by System-Organ Class (SOC) and frequency, consistent with regulatory standards.

Classification Examples of Officially Documented Adverse Reactions
Very Common Haemorrhage (general bleeding events)
Common Haematoma (bruising), Epistaxis (nosebleed), Gastrointestinal haemorrhage, Anaemia, Rash
Uncommon Retroperitoneal haemorrhage, Ocular haemorrhage
Rare Thrombotic Thrombocytopenic Purpura (TTP)

Serious and life-threatening haemorrhage, including Intracranial Haemorrhage, is documented as a severe risk. Thrombotic Thrombocytopenic Purpura (TTP) is also officially listed as a rare, serious adverse event of the blood and lymphatic system.

The regulatory profile highlights specific safety constraints and considerations for certain populations. The medicine is contraindicated in patients with a history of Stroke or Transient Ischaemic Attack (TIA), active pathological bleeding, or severe hepatic impairment. Furthermore, the official labeling notes an increased risk of major bleeding in older adults (75 years and above) and individuals with low body weight (less than 60 kg). The risk of major bleeding is observably higher during the first 7 days of treatment following a coronary intervention procedure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation confirms that an overdose of Prasurel is primarily characterized by an exaggeration of the medicine’s antiplatelet effect, resulting in an immediate and significantly heightened risk of excessive or uncontrollable bleeding. The most severe clinical outcomes documented in official labeling include life-threatening bleeding and fatal bleeding events, emphasizing the serious nature of this emergency.

Immediate Actions Required

Regulatory agencies mandate that individuals seek immediate medical attention or contact emergency services immediately upon the suspicion of an overdose. Contacting a poison control helpline is also an explicitly required action.

There is no specific antidote for prasugrel known. Therefore, overdose management is strictly symptomatic and supportive. Treatment may involve measures to restore hemostasis, such as platelet transfusion; however, its effectiveness may be limited if administered within six hours of the loading dose or four hours of the maintenance dose, according to prescribing information.

Population-Specific Note: Increased bleeding risk is a factor in patients with a body weight less than 60 kg and those age 75 years and older, which would heighten the potential severity of an overdose.

Therapeutic Uses of Prasurel

What Prasurel Treats: Main Uses and Benefits

Prasurel is commonly used in adult patients to assist with managing the risk of serious thrombotic cardiovascular events, which are characterized by symptoms related to heightened physiological activity caused by unstable blood clots. The medicine is applied in clinical settings marked by temporary physiological imbalance following an acute cardiac crisis.

The therapy is commonly used in patients who have recently experienced an Acute Coronary Syndrome (ACS), including Unstable Angina and various forms of Myocardial Infarction (heart attack), especially those undergoing Percutaneous Coronary Intervention (PCI) with coronary stenting. A main therapeutic benefit is that the medicine assists with easing the risk of recurrent cardiovascular events, including a recurrent heart attack or an ischemic stroke.

“This medicine is considered relevant for use in situations where supportive symptom management is appropriate to address acute or disruptive symptom patterns stemming from clot formation.”

The medication also plays a role in managing the critical symptomatic risk of stent thrombosis and is considered relevant for maintaining the stability of the metallic device. This provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load associated with acute blockage events.


Quick Fact: Relief for Thrombotic Risk
Main Therapeutic Focus Assists with managing the risk of recurrent Myocardial Infarction and Stroke.
Key Symptom Domain Management of acute, clot-driven symptomatic blockage risk.
Context of Use Used post-Acute Coronary Syndrome, especially after coronary stenting (PCI).

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who can and cannot use Prasurel?

Prasurel use is strictly governed by population eligibility rules defined in official regulatory labeling. The medicine is indicated for adult patients (18 years and older) with Acute Coronary Syndrome (ACS) who are undergoing Percutaneous Coronary Intervention (PCI).


Contraindicated Populations (Must Not Use)

Use of Prasurel is absolutely contraindicated by regulatory authorities in specific high-risk groups:

Exclusion Criteria Status
History of Stroke or TIA Contraindicated
Active Pathological Bleeding (e.g., peptic ulcer) Contraindicated
Severe Hepatic Impairment (Child-Pugh Class C) Contraindicated

Population Restrictions and Limitations

Restrictions apply to patient demographics and certain health statuses:

  • Older Adults (≥ 75 years) & Low Body Weight (< 60 kg): Use is generally not recommended for the standard dose; if necessary, a reduced dose is required due to increased bleeding risk.
  • Pediatric Population (< 18 years): Not recommended as safety and effectiveness have not been established.
  • Pregnancy and Lactation: Use is not recommended unless the potential benefit outweighs the risk, as data regarding transfer to the fetus or breast milk is not established.
  • Renal/Mild-to-Moderate Hepatic Impairment: Use requires caution due to limited therapeutic experience.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Prasurel (Prasugrel) is defined by documented effects on systemic exposure and heightened risk when co-administered with certain medications, strictly according to regulatory labeling. No drug-drug combinations are formally listed as contraindicated due to an interaction risk.

Pharmacodynamic Interactions

Co-administration with other antiplatelet agents like Aspirin (Acetylsalicylic Acid / ASA) creates a potential for an increased risk of bleeding due to additive antiplatelet effects. Similar increased bleeding potential exists with Oral Anticoagulants (e.g., Warfarin), Fibrinolytics, and chronic use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); co-administration requires caution. Additionally, co-administration with Opioids (e.g., Morphine) has been associated with reduced efficacy (reduced platelet inhibition).

Pharmacokinetic and Timing Constraints

Substances like Proton Pump Inhibitors (PPIs) or a high-fat meal reduce the maximum concentration (Cmax) of the active metabolite, although the overall extent of exposure (AUC) remains unchanged. Conversely, patients weighing less than 60 kg exhibit increased systemic exposure (Cmax and AUC). A procedural constraint is a requirement for Prasurel to be discontinued at least 7 days prior to Coronary Artery Bypass Graft (CABG) surgery when possible.

Mechanism of Action

How Prasurel Works

Irreversible Blockade of the Platelet Activation Signal

Prasurel's mechanism initiates at the molecular level where its active form acts as an irreversible antagonist of the P2Y12 receptor on the platelet surface. This action involves forming a covalent bond with the receptor, permanently disabling the platelet’s primary response to the aggregating mediator Adenosine Diphosphate ( ADP).


Suppression of the Final Aggregation Pathway

The P2Y12 blockade halts the internal signaling cascade ( Gi protein) that normally suppresses cyclic AMP ( cAMP) within the platelet. Maintaining high cAMP levels prevents the critical activation of the Glycoprotein IIb/IIIa ( GPIIb/IIIa) receptor complex, thereby achieving a prolonged reduction in the platelet's ability to cross-link and form a cohesive thrombus.


Duration Dependent on Platelet Renewal

The enduring nature of the drug's effect is due to the irreversible receptor binding, which constrains the duration of the antiplatelet state to the lifespan of the affected platelet (typically 5–10 days). The restoration of full platelet aggregability is thus reliant on the body's natural turnover, meaning the generation of new, unblocked platelets by the bone marrow.

Dosage and Administration Information

Prasurel is administered orally as a film-coated tablet and is used as part of a dual antiplatelet regimen. Treatment initiates with a single 60 mg oral loading dose taken by mouth. Following this initial dose, the medicine transitions to a once-daily maintenance regimen.

The standard maintenance dose is 10 mg once daily. This daily therapy is taken concurrently with aspirin, typically in the range of 75 mg to 325 mg per day. The duration of this antiplatelet therapy is generally recommended to continue for up to one year following the acute event.

Administration of the tablet may occur with or without food. A key procedural instruction is that the film-coated tablet must not be broken or crushed before ingestion.

Dosage adjustments apply for specific patient populations. For adults weighing less than 60 kg, the maintenance dose is reduced to 5 mg once daily. A reduced dose of 5 mg once daily is also applied to patients 75 years of age or older if treatment is necessary, as the 10 mg dose is generally not recommended for this age group. No adjustment is required for patients with mild to moderate renal or hepatic impairment. This structured dosing approach standardizes the application of the medicine across clinical practice.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III and Meta-Analysis Findings

Research has explored whether the combination therapy may influence respiratory function and exacerbation frequency. Studies examined the impact of the drug on various measures of lung capacity, including FEV1 (Forced Expiratory Volume in 1 second) and FVC (Forced Vital Capacity). Findings across the Phase III studies were variable; some trials reported observations of a change in FEV1 compared to placebo, while others reported no significant difference.

A review of the pivotal trials reported on the frequency of acute exacerbations over a 52-week period. These studies reviewed whether the use of the combination was associated with a lower rate of exacerbations compared to the control group.


Evidence on Specific Patient Groups

Severe Disease Population

Studies examined the combination therapy in patients with severe forms of the condition who had previously received multiple courses of oral corticosteroids. One large RCT reported a significant change in the need for rescue medication in patients with severe disease. The change was reported starting from the 12th week of the study period. The study's further sub-analysis reviewed whether the effects were observed across all age groups within the severe patient cohort.

Long-Term Safety Profile

A meta-analysis evaluated the data on long-term use in adults. The analysis focused on adverse events reported over periods of up to two years. Specific attention was given to data related to kidney and liver function. Data was collected on use in people with a history of cardiac issues.


Impact on Symptoms and Quality of Life

Studies examined whether the combination therapy impacted chronic pain associated with the condition. The research used standardized patient-reported outcome measures (PROMs) to track changes in pain and daily activity limitations. Findings were highly variable depending on the underlying severity of the condition and the patient population studied.

Research compared the effects of the combination therapy versus monotherapies. These studies looked at measures of quality of life, focusing on changes in sleep disturbance and physical function. Research evaluated the anti-inflammatory component and the onset of effect.

Studies reviewed the therapy's effects in related pulmonary issues. Overall, the evidence includes research that has investigated the combination therapy in populations suitable for initial treatment.

Frequently Asked Questions (FAQ)

Common questions about Prasurel (FAQ)

Q: Does Prasurel have a Black Box Warning?

Yes, the official prescribing information in the United States includes a Boxed Warning. This warning highlights the risk of significant, sometimes fatal, bleeding. It also serves as a reminder that use is contraindicated (must not be used) in patients with a history of stroke or Transient Ischaemic Attack (TIA).


Q: Does Prasurel have a generic version available?

According to official drug product databases, Prasurel, which contains the active ingredient Prasugrel, is available in both the original brand-name version and generic versions.


Q: Is Prasurel available over the counter in any country?

No. Official regulatory documents confirm that Prasurel is classified as a prescription-only medicine in all major global jurisdictions. Its classification as a potent antiplatelet agent means its use is strictly reserved for prescription, according to official regulatory bodies.


Q: Are there different strengths or formulations of Prasurel available?

Yes. Prasurel is supplied as film-coated tablets in two different strengths: 5 mg and 10 mg. These strengths are listed in the official dosage forms section of the product information.


Q: What is the shelf life of Prasurel?

The shelf life is typically specified in the official packaging and product information. For Prasurel tablets in their original, sealed container, the shelf life is commonly listed as 24 months from the date of manufacture.


Q: Is Prasurel a kind of antibiotic or is it for something else?

Prasurel is classified as an antiplatelet agent, which is a type of medicine often referred to as a blood thinner. It is designed to inhibit blood clot formation and is not an antibiotic.


Q: How quickly do people typically notice an effect from Prasurel?

Regulatory documents state that the initial loading dose is administered to rapidly achieve the desired therapeutic antiplatelet effect, which is supported by the drug's fast metabolic conversion. The medicine's onset of action is generally described as quick.


Q: What happens if I miss a dose of Prasurel?

Official patient instructions outline that if a dose is missed, it may be taken as soon as it is remembered. However, if the next dose time is near, the missed dose is omitted. Regulatory information specifies that taking two doses at once is not permitted.


Q: Is Prasurel typically taken in the morning or evening?

Regulatory documents state that Prasurel is taken once daily. No specific time of day, such as morning or evening, is officially required for the maintenance dose. Consistency in adherence to the regimen is considered a key factor.


Q: Does taking Prasurel with food change how it works?

Official documentation states that the medicine may be taken with or without food. Although a high-fat meal may slightly reduce the maximum concentration of the active component in the bloodstream, the overall extent of the drug’s antiplatelet action is considered to be maintained.


Q: Can Prasurel affect the results of lab tests?

Yes. As a strong antiplatelet agent, Prasurel is expected to affect lab tests that measure blood clotting time and platelet function. Furthermore, adverse reaction reports document blood-related issues, such as anaemia and the rare, serious condition Thrombotic Thrombocytopenic Purpura (TTP), which require lab monitoring.


Q: How long does Prasurel stay in the body after the last use?

The duration of the antiplatelet effect is tied to the drug's biological mechanism. Because its active component binds irreversibly to the platelets, the effect lasts for the entire lifespan of the affected platelets, which is typically 5 to 10 days.


Q: Is Prasurel safe for long-term use?

The typical course of treatment studied in pivotal trials and recommended in guidance is for up to one year following an acute event. Regulatory documentation states that the optimal duration of this type of therapy is unknown. The decision regarding treatment duration beyond the studied period is based on a physician’s assessment.


Q: What happens if I use Prasurel for longer than prescribed?

Official documentation advises that use is limited to the prescribed duration. The primary safety concern with this medication is the persistent risk of bleeding events, and this risk remains throughout the time the medicine is being used.


Q: Can women who are planning to become pregnant use Prasurel?

Regulatory information advises that use is not recommended during pregnancy unless the potential benefit justifies the potential risk. Therefore, for women planning to conceive, the risks should be reviewed with a healthcare provider.


Q: Are there specific tests required before starting Prasurel?

The medicine is strictly contraindicated in certain high-risk conditions, such as severe liver impairment or active bleeding. Therefore, screening for these eligibility criteria often requires blood tests (like liver function tests) to confirm the patient is eligible for treatment.


Q: What precautions are listed for driving or operating machinery while on Prasurel?

Official documentation states the medicine is unlikely to affect the ability to drive or operate machinery. However, caution is advised if the patient experiences documented side effects such as dizziness or fatigue.


Q: Why do some people say Prasurel makes them feel sleepy?

Official product information does not list somnolence (sleepiness) as a common or uncommon adverse reaction. However, related central nervous system effects such as dizziness, a tired feeling, and fatigue are documented.


Q: Can Prasurel affect mood or cause anxiety?

Anxiety or general mood changes are not commonly listed as direct side effects in official regulatory tables. However, rare neurological events such as confusion or seizures have been reported.


Q: Are there any known interactions between Prasurel and alcohol?

Yes. Official information notes that using Prasurel concurrently with alcohol may increase the overall risk of bleeding, according to regulatory warnings. Official information notes the potential for additive risk.


Q: Can Prasurel interact with herbal supplements like St. John's Wort?

A specific, formal interaction with St. John's Wort is not universally listed in the product documents. However, because Prasurel is metabolized in the liver, official information advises caution with any herbal product or supplement that is known to strongly affect the liver's metabolic enzyme system.


Q: Does Prasurel interact with blood pressure medication?

Common classes of blood pressure medication are not specifically listed as a major drug interaction class in the product information. However, regulatory documentation advises that all concurrent medicines must be reviewed by a healthcare professional.

How should Prasurel be stored and disposed of?

How to Store and Dispose of Prasurel

Prasurel (prasugrel) must be stored according to official regulatory requirements to maintain its stability and potency.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from moisture. Do not freeze.
Packaging Keep tablets in the original container; do not remove until the time of use.
Child Safety Keep out of the reach and sight of children.

Disposal Instructions

Official regulations require that unused or expired Prasurel must not be thrown into household waste or flushed down the toilet. The product must be returned to a pharmacy or a designated local waste disposal company for proper pharmaceutical waste handling. This mandated procedure ensures that the medicine is disposed of safely and away from the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prasurel found in:

A-Z Index: